Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.48 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816805 | 0.94 | KISS1R (0.52) | GPR132KISS1RMMEACE | |
| SCHEMBL29413325 | 0.92 | MME (0.49) | GPR132KISS1RCMKLR2CMKLR1MME | |
| SCHEMBL29383060 | 0.92 | MME (0.49) | GPR132KISS1RCMKLR2CMKLR1MME | |
| SCHEMBL4198783 | 0.92 | GPR132 (0.52) | GPR132CMKLR2CMKLR1MMECTSC | |
| SCHEMBL29892331 | 0.89 | MME (0.58) | MMECTSCGNPATACECPA1 | |
| SCHEMBL30509011 | 0.88 | GPR132 (0.50) | GPR132KISS1RMMEGNPATTBXAS1 | |
| Trifluoroacetic Acid SCHEMBL2367272 | 0.88 | MME (0.46) | GPR132KISS1RCMKLR2CMKLR1MME | |
| SCHEMBL30519203 | 0.87 | MME (0.54) | GPR132CMKLR2CMKLR1MMEACE | |
| SCHEMBL30759355 | 0.87 | GPR132 (0.48) | GPR132KISS1RCMKLR2CMKLR1MME | |
| SCHEMBL29390652 | 0.87 | MME (0.49) | GPR132KISS1RCMKLR2CMKLR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | GPR132 226/4885KISS1R 2149/4885CMKLR2 1168/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | GPR132 226/4885KISS1R 2149/4885CMKLR2 1168/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | GPR132 2043/4885KISS1R 2023/4885CMKLR2 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.